Abstract
For an adolescent with bacterial meningitis and subsequent cerebral aspergillosis, intravenous voriconazole dose requirements substantially decreased during coadministration with intravenous chloramphenicol and considerably rose after discontinuation of the antibiotic. In agreement with in vitro evidence, these data suggest that chloramphenicol is a rather significant inhibitor of hepatic CYP3A4 and/or CYP2C19.
MeSH terms
-
Adolescent
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / adverse effects*
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / metabolism*
-
Aryl Hydrocarbon Hydroxylases / antagonists & inhibitors
-
Chloramphenicol / administration & dosage
-
Chloramphenicol / adverse effects*
-
Cytochrome P-450 CYP2C19
-
Cytochrome P-450 CYP3A
-
Cytochrome P-450 CYP3A Inhibitors
-
Drug Interactions
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / adverse effects
-
Humans
-
Liver / drug effects
-
Liver / enzymology
-
Male
-
Neuroaspergillosis / drug therapy*
-
Neuroaspergillosis / metabolism*
-
Pyrimidines / administration & dosage
-
Pyrimidines / blood
-
Pyrimidines / cerebrospinal fluid
-
Pyrimidines / metabolism*
-
Triazoles / administration & dosage
-
Triazoles / blood
-
Triazoles / cerebrospinal fluid
-
Triazoles / metabolism*
-
Voriconazole
Substances
-
Anti-Bacterial Agents
-
Antifungal Agents
-
Cytochrome P-450 CYP3A Inhibitors
-
Enzyme Inhibitors
-
Pyrimidines
-
Triazoles
-
Chloramphenicol
-
Aryl Hydrocarbon Hydroxylases
-
CYP2C19 protein, human
-
Cytochrome P-450 CYP2C19
-
Cytochrome P-450 CYP3A
-
CYP3A4 protein, human
-
Voriconazole